TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Treatment Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Nephroblastoma Treatment Market, by Types
6.1 Introduction
6.2 Favorable histology
6.2.1 Market Estimates & Forecast, 2020-2027
6.3 Unfavorable histology
6.3.1 Market Estimates & Forecast, 2020-2027
Chapter 7. Global Nephroblastoma Treatment Market, by drug
7.1 Introduction
7.2 Dactinomycin (cosmegen)
7.2.1 Market Estimates & Forecast, 2020-2027
7.3 Doxorubicin (adriamycin)
7.3.1 Market Estimates & Forecast, 2020-2027
7.4 Vincristine (vincasar pfs, oncovin)
7.4.1 Market Estimates & Forecast, 2020-2027
7.5 Cyclophosphamide (cytoxan, neosar)
7.5.1 Market Estimates & Forecast, 2020-2027
7.6 Etoposide (toposar, vepesid)
7.6.1 Market Estimates & Forecast, 2020-2027
7.7 Irinotecan (camptosar)
7.7.1 Market Estimates & Forecast, 2020-2027
7.8 Others
Chapter 8. Global Nephroblastoma Treatment Market, by diagnosis
8.1 Introduction
8.2 Ultrasound
8.2.1 Market Estimates & Forecast, 2020-2027
8.3 Computerized tomography (CT)
8.3.1 Market Estimates & Forecast, 2020-2027
8.4 Magnetic resonance imaging (MRI)
8.4.1 Market Estimates & Forecast, 2020-2027
8.5 Chest x-ray
8.5.1 Market Estimates & Forecast, 2020-2027
8.6 Bone scan
8.6.1 Market Estimates & Forecast, 2020-2027
8.7 Lab tests
8.7.1 Market Estimates & Forecast, 2020-2027
8.8 Others
Chapter 9. Global Nephroblastoma Treatment Market, by treatment
9.1 Introduction
9.2 Surgery
9.2.1 Market Estimates & Forecast, 2020-2027
9.2.2 Radical nephrectomy
9.2.2.1 Market Estimates & Forecast, 2020-2027
9.2.3 Partial nephrectomy (nephron-sparing surgery)
9.2.3.1 Market Estimates & Forecast, 2020-2027
9.2.4 Others
9.3 Chemotherapy
9.3.1 Market Estimates & Forecast, 2020-2027
9.4 Radiation therapy
9.4.1 Market Estimates & Forecast, 2020-2027
9.5 Others
Chapter 10. Global Nephroblastoma Treatment Market, by Distribution channel
10.1 Introduction
10.2 Hospital pharmacies
10.2.1 Market Estimates & Forecast, 2020-2027
10.3 E-commerce
10.3.1 Market Estimates & Forecast, 2020-2027
10.4 Drug stores
10.4.1 Market Estimates & Forecast, 2020-2027
10.5 Retail pharmacy
10.5.1 Market Estimates & Forecast, 2020-2027
10.6 Others
Chapter 11. Global Nephroblastoma Treatment Market, by End User
11.1 Introduction
11.2 Hospitals
11.2.1 Market Estimates & Forecast, 2020-2027
11.3 Cancer centers
11.3.1 Market Estimates & Forecast, 2020-2027
11.4 Surgical centers
11.4.1 Market Estimates & Forecast, 2020-2027
11.5 Ambulatory surgical center
11.5.1 Market Estimates & Forecast, 2020-2027
Chapter. 12 Global Nephroblastoma Treatment Market, by Region
12.1 Introduction
12.2 Americas
12.2.1 North America
12.2.1.1 U.S.
12.2.1.1 Canada
12.2.2 South America
12.3 Europe
12.3.1 Western Europe
12.3.1.1 Germany
12.3.1.2 France
12.3.1.3 Italy
12.3.1.4 Spain
12.3.1.5 U.K
12.3.1.6 Rest of Western Europe
12.3.2 Eastern Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 Republic of Korea
12.4.6 Rest of Asia Pacific
12.5 The Middle East & Africa
12.5.1 United Arab Emirates
12.5.2 Saudi Arabia
12.5.3 Rest of the Middle East & Africa
Chapter 13 Company Landscape
13.1 Introduction
13.2 Market Share Analysis
13.3 Key Development & Strategies
13.3.1 Key Developments
Chapter 14 Company Profiles
14.1 Bayer HealthCare LLC
14.1.1 Company Overview
14.1.2 Treatment Overview
14.1.3 Financials
14.1.4 SWOT Analysis
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Company Overview
14.2.2 Treatment Overview
14.2.3 Financial Overview
14.2.4 Key Developments
14.2.5 SWOT Analysis
14.3 Pfizer Inc.
14.3.1 Company Overview
14.3.2 Treatment Overview
14.3.3 Financial Overview
14.3.4 Key Development
14.3.5 SWOT Analysis
14.4 Sanofi Pasteur Inc.
14.4.1 Company Overview
14.4.2 Treatment/Business Segment Overview
14.4.3 Financial Overview
14.4.4 Key Development
14.4.5 SWOT Analysis
14.5 Merck & Co. Inc.
14.5.1 Company Overview
14.5.2 Treatment Overview
14.5.3 Financial overview
14.5.4 Key Developments
14.6 MediLexicon International Ltd
14.6.1 Company Overview
14.6.2 Treatment Overview
14.6.3 Financial Overview
14.6.4 Key Developments
14.7 Bristol-Myers Squibb Company
14.7.1 Overview
14.7.2 Treatment Overview
14.7.3 Financials
14.7.4 Key Developments
14.7.5 SWOT Analysis
14.8 Apotex Inc.
14.8.1 Company Overview
14.8.2 Treatment/Business Segment Overview
14.8.3 Financial Overview
14.8.4 Key Development
14.8.5 SWOT Analysis
14.9 Others
Chapter 15 MRFR Conclusion
15.1 Key Findings
15.1.1 From CEO’s View Point
15.1.2 Unmet Needs of the Market
15.2 Key Companies to Watch
15.3 Prediction of Pharmaceutical industry
Chapter 16 Appendix
LIST OF TABLES
Table 1 Nephroblastoma treatment Industry Synopsis, 2020-2027
Table 2 Nephroblastoma treatment Market Estimates and Forecast, 2020-2027, (USD Million)
Table 3 Nephroblastoma treatment Market by Region, 2020-2027, (USD Million)
Table 4 Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 5 Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 6 Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 7 Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 8 Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 9 Nephroblastoma treatment Market by End Users, 2020-2027, (USD Million)
Table 10 North America Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 11 North America Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 12 North America Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 13 North America Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 14 North America Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 15 North America Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
Table 16 US Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 17 US Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 18 US Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 19 US Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 20 US Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 21 US Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
Table 22 Canada Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 23 Canada Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 24 Canada Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 25 Canada Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 26 Canada Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 27 Canada Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
Table 28 South America Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 29 South America Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 30 South America Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 31 South America Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 32 South America Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 33 South America Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
Table 34 Europe Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 35 Europe Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 36 Europe Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 37 Europe Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 38 Europe Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 39 Europe Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
Table 40 Western Europe Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 41 Western Europe Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 42 Western Europe Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 43 Western Europe Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 44 Western Europe Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 45 Western Europe Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
Table 46 Eastern Europe Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 47 Eastern Europe Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 48 Eastern Europe Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 49 Eastern Europe Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 50 Eastern Europe Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 51 Eastern Europe Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
Table 52 Asia Pacific Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 53 Asia Pacific Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 54 Asia Pacific Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 55 Asia Pacific Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 56 Asia Pacific Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 57 Asia Pacific Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
Table 58 The Middle East & Africa Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)
Table 59 The Middle East & Africa Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)
Table 60 The Middle East & Africa Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)
Table 61 The Middle East & Africa Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)
Table 62 The Middle East & Africa Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)
Table 63 The Middle East & Africa Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Nephroblastoma treatment Market
Figure 3 Segmentation Market Dynamics for Nephroblastoma treatment Market
Figure 4 Global Nephroblastoma treatment Market Share, by Type 2020-2027
Figure 5 Global Nephroblastoma treatment Market Share, by Drugs 2020-2027
Figure 6 Global Nephroblastoma treatment Market Share, by Diagnosis, 2020-2027
Figure 7 Global Nephroblastoma treatment Market Share, by Treatment, 2020-2027
Figure 8 Global Nephroblastoma treatment Market Share, by Distribution Channel, 2020-2027
Figure 9 Global Nephroblastoma treatment Market Share, by End Users, 2020-2027
Figure 10 Global Nephroblastoma treatment Market Share, by Region, 2020-2027
Figure 11 North America Nephroblastoma treatment Market Share, by Country, 2020-2027
Figure 12 Europe Nephroblastoma treatment Market Share, by Country, 2020-2027
Figure 13 Asia Pacific Nephroblastoma treatment Market Share, by Country, 2020-2027
Figure 14 The Middle East & Africa Nephroblastoma treatment Market Share, by Country, 2020-2027
Figure 15 Global Nephroblastoma treatment Market: Company Share Analysis, 2020-2027 (%)
Figure 16 Bayer HealthCare LLC: Key Financials
Figure 17 Bayer HealthCare LLC: Segmental Revenue
Figure 18 Bayer HealthCare LLC: Geographical Revenue
Figure 19 F. Hoffmann-La Roche Ltd: Key Financials
Figure 20 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 21 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 22 Pfizer Inc.: Key Financials
Figure 23 Pfizer Inc.: Segmental Revenue
Figure 24 Pfizer Inc.: Geographical Revenue
Figure 25 Sanofi Pasteur Inc.: Key Financials
Figure 26 Sanofi Pasteur Inc.: Segmental Revenue
Figure 27 Sanofi Pasteur Inc.: Geographical Revenue
Figure 28 Merck & Co. Inc.: Key Financials
Figure 29 Merck & Co. Inc.: Segmental Revenue
Figure 31 Merck & Co. Inc.: Geographical Revenue
Figure 32 MediLexicon International Ltd: Key Financials
Figure 33 MediLexicon International Ltd: Segmental Revenue
Figure 34 MediLexicon International Ltd: Geographical Revenue
Figure 35 Bristol-Myers Squibb Company: Key Financials
Figure 36 Bristol-Myers Squibb Company: Segmental Revenue
Figure 37 Bristol-Myers Squibb Company: Geographical Revenue
Figure 38 Apotex Inc: Key Financials
Figure 39 Apotex Inc: Segmental Revenue
Figure 40 Apotex Inc: Geographical Revenue
